Fold changes for the 5 genes in ET, PV, and PMF compared to control subjects.

<p>Patient groups and genes are shown on the x-axis and fold changes on the Y-axis. NS: non-significant; S: significant. All genes FDR<0.05.</p

Hierarchical Cluster analysis with euclidean distance in ET, PV and PMF patients.

<p>Rows in the heat map represent the five genes DEFA4, ELA2, CTSG, OLFM4, and AZU1, and columns represent patients. The color key ranges from green to red representing standardized expression values of −3.0 to 3.0. Green indicates low expression, black intermediate expression, and red high expression. Five major clusters can be identified. Cluster 1 (green, low expression), cluster 2 (green-black, low-intermediate expression), cluster 3 (black-red, intermediate expression), cluster 4 (red-black, intermediate-high expression), and cluster 5 (red, high expression).The dendogram shows the degree of similarity between patients.</p

Clinical and Biochemical Data in Cluster 1–5 with low, low-intermediate, intermediate, intermediate-high, and high expression values of the 5 genes, respectively.

<p>Median and range are shown. Abbreviations: ET =  Essential Thrombocythemia; PV =  Polycythemia Vera; PMF =  Primary Myelofibrosis; *  =  blood tests at the time of blood sampling for gene expression profiling; disease duration at the time of blood sampling; **:from diagnosis as assessed January 2013.</p

The top 20 most downregulated oxidative stress and antioxidative defense genes in patients with ET, PV, and PMF (FDR <0.05).

<p>FC: fold change. FDR: false discovery rate.</p><p>The results from data set 1 are compared with results from data set 2.</p><p>The top 20 most downregulated oxidative stress and antioxidative defense genes in patients with ET, PV, and PMF (FDR <0.05).</p

Patient characteristics–Data set 1.

<p>Age: Median and range; Disease duration: Median and range; V617F allele burden %: median and 95% confidence interval. Therapy: HU  =  hydroxyurea, IFN  =  recombinant interferon-alfa, ANA  =  anagrelide; BU  =  busulfan.</p><p>Patient characteristics–Data set 1.</p

Patient characteristics–Data set 2.

<p>Age: Median and range; Disease duration: Median and range; V617F allele burden %: median and 95% confidence interval. HU  =  hydroxyurea, ANA  =  anagrelide.</p><p>Patient characteristics–Data set 2.</p

Hematological data–Data set 1.

<p>Hemoglobin concentration and cell counts are presented as medians with 95% confidence intervals in parenthesis. NA: Not applicable. NS: Not significant.</p><p>Hematological data–Data set 1.</p

Flowchart illustrating the background for analytical approaches.

<p>Flowchart illustrating the background for analytical approaches.</p

Baseline subject characteristics.

<p>Values are number (column-%) or means (SD). <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0099388#pone.0099388-Hemminki1" target="_blank">[1]</a> Lymphoproliferative cancer defined as Hodgkin's lymphoma, non-Hodgkin lymphoma and chronic lymphocytic leukemia, <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0099388#pone.0099388-Chakravarty1" target="_blank">[2]</a> Calculated on previous hospital contacts (<3 years), <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0099388#pone.0099388-Khurana1" target="_blank">[3]</a>>10 mg/L, <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0099388#pone.0099388-Mercer1" target="_blank">[4]</a>>0.5•10⁹/L.</p